Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme.

Abstract

BACKGROUND:

A daily injection of low-molecular-weight heparin (LMWH) is often prescribed to women with unexplained recurrent pregnancy loss (RPL), although evidence suggesting a benefit is questionable.

OBJECTIVE:

To determine whether LMWH increases ongoing pregnancy and live-birth rates in women with unexplained RPL.

DESIGN:

Controlled, multicenter trial with randomization using minimization conducted from 2006 to 2013. (ClinicalTrials.gov: NCT00400387).

SETTING:

14 university hospitals and perinatal care centers in Germany and Austria.

PATIENTS:

449 women with at least 2 consecutive early miscarriages or 1 late miscarriage were included during 5 to 8 weeks' gestation after a viable pregnancy was confirmed by ultrasonography.

INTERVENTION:

Women in the control group received multivitamin pills, and the intervention group received vitamins and 5000 IU of dalteparin-sodium for up to 24 weeks' gestation.

MEASUREMENTS:

Primary outcome was ongoing pregnancy at 24 weeks' gestation. Secondary outcomes included the live-birth rate and late pregnancy complications.

RESULTS:

At 24 weeks' gestation, 191 of 220 pregnancies (86.8%) and 188 of 214 pregnancies (87.9%) were intact in the intervention and control groups, respectively (absolute difference, -1.1 percentage points [95% CI, -7.4 to 5.3 percentage points]). The live-birth rates were 86.0% (185 of 215 women) and 86.7% (183 of 211 women) in the intervention and control groups, respectively (absolute difference, -0.7 percentage point [CI, -7.3 to 5.9 percentage points]). There were 3 intrauterine fetal deaths (1 woman had used LMWH); 9 cases of preeclampsia or the hemolysis, elevated liver enzyme level, and low platelet count (HELLP) syndrome (3 women had used LMWH); and 11 cases of intrauterine growth restriction or placental insufficiency (5 women had used LMWH).

LIMITATION:

Placebo injections were not used, and neither trial staff nor patients were blinded.

CONCLUSION:

Daily LMWH injections do not increase ongoing pregnancy or live-birth rates in women with unexplained RPL. Given the burden of the injections, they are not recommended for preventing miscarriage.

PRIMARY FUNDING SOURCE:

Pfizer Pharma.

• Authors: Ekkehard Schleussner, Gabriele Kamin, Gregor Seliger, Nina Rogenhofer, Susanne Ebner, Bettina Toth, Michael Schenk, Melanie Henes, Michael K Bohlmann, Thorsten Fischer, Oana Brosteanu, Rupert Bauersachs, David Petroff, ETHIG II group
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 162 Issue 9 Pg. 601-9 (May 05 2015) ISSN: 1539-3704 [Electronic] United States
• PMID: 25938990 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anticoagulants
• Heparin, Low-Molecular-Weight
• Vitamins
• Dalteparin

Topics

• Abortion, Habitual (prevention & control)
• Anticoagulants (administration & dosage, therapeutic use)
• Dalteparin (therapeutic use)
• Female
• Heparin, Low-Molecular-Weight (administration & dosage, therapeutic use)
• Humans
• Injections, Subcutaneous
• Live Birth
• Pregnancy
• Vitamins (therapeutic use)